Tracers / [177Lu]Lu-PEG-Nb159
[177Lu]Lu-PEG-Nb159
Also written as [Lu-177]Lu-PEG-Nb159
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- PEGylated anti-FAP nanobody conjugated with DOTA chelator
- Target / mechanism
- Targets fibroblast activation protein (FAP) via a nanobody (Nb159) PMID 41460404
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/zr89-pegnb159/">zr89-pegnb159</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 94.6% | 92.97% | PEG-DOTA-Nb159 | 41460404 2025 EJNMMI Radiopharm Chem 370 MBq of 177Lu-chloride solution (Oak Ridge National Laboratory) was diluted with 200 µl of 1 M ammonium Acetate pH 5, supplemented with 3.5 mM ascorbic acid and 3.5 mM gentisic acid (MilliporeSigma), and added to 200 µl of 2 mg DOTA-functionalized Nb or substrate, in HEPES/NaCl buffer. — achieving a radiochemical purity of 92.97% and a yield of 94.6% |
Need this precursor?We can point you to suppliers for [177Lu]Lu-PEG-Nb159, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41460404. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41460404: 'PEG-DOTA-Nb159 or Gly3-PEG3-Lys(Azide)-PEG3-K(DOTA) substrate was labeled with Lutetium-177 (177Lu)'. Stage set/updated at stage 23 from PMID 41460404: 'for therapeutic evaluation in mice bearing FAP-positive U87 tumor xenografts.'.